Should I buy or sell Exact Sciences stock right now?

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Exact Sciences in the last twelve months. There are currently 2 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" EXAS shares. View EXAS analyst ratings or view top-rated stocks .

What is Exact Sciences' stock price target for 2024?

14 Wall Street analysts have issued 1-year price objectives for Exact Sciences' shares. Their EXAS share price targets range from $73.00 to $121.00. On average, they anticipate the company's share price to reach $97.44 in the next year. This suggests a possible upside of 54.1% from the stock's current price. View analysts price targets for EXAS or view top-rated stocks among Wall Street analysts .

How have EXAS shares performed in 2024?

Exact Sciences' stock was trading at $73.98 at the start of the year. Since then, EXAS shares have decreased by 14.5% and is now trading at $63.22. View the best growth stocks for 2024 here .

When is Exact Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our EXAS earnings forecast .

How can I listen to Exact Sciences' earnings call?

Exact Sciences will be holding an earnings conference call on Wednesday, May 8th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link .

How were Exact Sciences' earnings last quarter?

Exact Sciences Co. (NASDAQ:EXAS) posted its earnings results on Wednesday, February, 21st. The medical research company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.26. The medical research company earned $646.89 million during the quarter, compared to analysts' expectations of $638.83 million. Exact Sciences had a negative net margin of 8.17% and a negative trailing twelve-month return on equity of 6.60%. Exact Sciences's quarterly revenue was up 17.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.72) EPS.

What ETFs hold Exact Sciences' stock?

ETFs with the largest weight of Exact Sciences (NASDAQ:EXAS) stock in their portfolio include ARK Genomic Revolution ETF (ARKG) , First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) , Principal Healthcare Innovators ETF (BTEC) , Simplify Health Care ETF (PINK) , First Trust NYSE Arca Biotechnology Index Fund (FBT) , VanEck Biotech ETF (BBH) , Alger Mid Cap 40 ETF (FRTY) and Goldman Sachs Future Health Care Equity ETF (GDOC) .

What guidance has Exact Sciences issued on next quarter's earnings?

Exact Sciences issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.8 billion-$2.9 billion, compared to the consensus revenue estimate of $2.8 billion.

What is Kevin T. Conroy's approval rating as Exact Sciences' CEO?

328 employees have rated Exact Sciences Chief Executive Officer Kevin T. Conroy on Glassdoor.com . Kevin T. Conroy has an approval rating of 97% among the company's employees. This puts Kevin T. Conroy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 69.0% of employees surveyed would recommend working at Exact Sciences to a friend.

What other stocks do shareholders of Exact Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Exact Sciences investors own include Novavax (NVAX) , NVIDIA (NVDA) , Alibaba Group (BABA) , Micron Technology (MU) , Salesforce (CRM) , PayPal (PYPL) , Block (SQ) , Advanced Micro Devices (AMD) , Walt Disney (DIS) and AbbVie (ABBV) .

Who are Exact Sciences' major shareholders?

Exact Sciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Global Assets Advisory LLC (0.14%), Factory Mutual Insurance Co. (0.10%), Thompson Investment Management Inc. (0.09%), Traynor Capital Management Inc. (0.05%), Beech Hill Advisors Inc. (0.03%) and Gateway Investment Advisers LLC (0.02%). Insiders that own company stock include Brian Baranick , Canada Pension Plan Investment, D Scott Coward , Daniel J Levangie, Everett Cunningham , Jacob A Orville , James Edward Doyle , James Herriott , Jeffrey Thomas Elliott , Katherine S Zanotti , Kevin T Conroy and Sarah Condella . View institutional ownership trends .

How do I buy shares of Exact Sciences?

Shares of EXAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Does Exact Sciences have any subsidiaries?

The following companies are subsidiares of Exact Sciences: Armune BioScience, Ashion Analytics, Base Genomics Limited, Biomatrica Inc., Exact Sciences Development Company LLC, Exact Sciences Laboratories LLC, Genomic Health Inc., Genomic Health International Holdings LLC, Paradigm Diagnostics Inc., Sampleminded Inc., Thrive Earlier Detection Corporation, and Viomics Inc.. Read More

Top-Rated StocksTop-Rated

NASDAQ:EXAS

Exact Sciences (EXAS) Stock Price, News & Analysis

→ Uncover this 2024 Hidden Gem (From Tips4Traders) (Ad)

Free EXAS Stock Alerts

$63.22

-0.64 (-1.00%)

(As of 04/17/2024 ET)

Compare

Today's Range: $62.91
▼
$66.74
50-Day Range: $56.27
▼
$74.26
52-Week Range: $56.05
▼
$100.77

Volume: 2.52 million shs
Average Volume: 2.33 million shs
Market Capitalization: $11.48 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $97.44

Get Exact Sciences alerts:

Exact Sciences MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.86 Rating Score
Upside/Downside: 54.1% Upside
$97.44 Price Target
Short Interest: Healthy
3.49% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.83
Upright™ Environmental Score
News Sentiment: 0.71
Based on 12 Articles This Week
Insider Trading: Selling Shares
$4.17 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.86) to $0.02 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.38 out of 5 stars

Medical Sector

106th out of 913 stocks

Medical Laboratories Industry

5th out of 18 stocks

3.4

Analyst's Opinion

Consensus Rating
Exact Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 12 buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Exact Sciences has only been the subject of 3 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
3.49% of the outstanding shares of Exact Sciences have been sold short.
Short Interest Ratio / Days to Cover
Exact Sciences has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Exact Sciences has recently decreased by 2.76%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Exact Sciences does not currently pay a dividend.
Dividend Growth
Exact Sciences does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Exact Sciences has received a 74.50% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Private genetic testing services", "Biochemical assay kits for colorectal cancer diagnostics", and "Biochemical assay kits for liver cancer diagnostics" products. See details.
Environmental Sustainability
The Environmental Impact score for Exact Sciences is -0.83.

2.6

News and Social Media Coverage

News Sentiment
Exact Sciences has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 12 news articles for Exact Sciences this week, compared to 7 articles on an average week.
Search Interest
Only 21 people have searched for EXAS on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.
MarketBeat Follows
Only 17 people have added Exact Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -26% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Exact Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,165,273.00 in company stock.
Percentage Held by Insiders
Only 1.30% of the stock of Exact Sciences is held by insiders.
Percentage Held by Institutions
88.82% of the stock of Exact Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Exact Sciences are expected to grow in the coming year, from ($0.86) to $0.02 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Exact Sciences is -55.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Exact Sciences is -55.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Exact Sciences has a P/B Ratio of 3.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Insiders Exposed

This consistently signaled gains of 453%... 610%... and even 1036%...

It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.

About Exact Sciences Stock (NASDAQ:EXAS)

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

EXAS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

EXAS Stock News Headlines

April 4, 2024 | insidertrades.com

Exact Sciences Co. (NASDAQ:EXAS) EVP Sells $140,000.00 in Stock

April 17, 2024 | finance.yahoo.com

Exact Sciences Corporation's (NASDAQ:EXAS) Profit Outlook

April 18, 2024 | Darwin (Ad)

Your Next Portfolio Star: Revealing 2024's Top Stock Pick

We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)

April 17, 2024 | americanbankingnews.com

Exact Sciences Sees Unusually Large Options Volume (NASDAQ:EXAS)

April 15, 2024 | markets.businessinsider.com

Exact Sciences Appoints Aaron Bloomer As Chief Financial Officer

April 15, 2024 | businesswire.com

Exact Sciences Names Aaron Bloomer as New Chief Financial Officer

April 13, 2024 | americanbankingnews.com

Exact Sciences (NASDAQ:EXAS) Shares Gap Down to $73.60

April 12, 2024 | finance.yahoo.com

Here’s Why Exact Sciences Corporation (EXAS) Declined in Q1

April 18, 2024 | Darwin (Ad)

Your Next Portfolio Star: Revealing 2024's Top Stock Pick

April 11, 2024 | businesswire.com

Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes

April 10, 2024 | finance.yahoo.com

Exact Sciences (EXAS) Stock Moves -0.89%: What You Should Know

April 10, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Exact Sciences on Promising Multi-Cancer Detection Technology

April 8, 2024 | forbes.com

How This CEO Consumerized Cancer Diagnostics Into A $13B Enterprise

April 8, 2024 | businesswire.com

Exact Sciences to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR Annual Meeting 2024

April 8, 2024 | finance.yahoo.com

Sorry, but Blood Tests Won’t Replace Stool Samples or Colonoscopies Yet

April 8, 2024 | businesswire.com

Exact Sciences Schedules First Quarter 2024 Earnings Call

April 8, 2024 | americanbankingnews.com

Exact Sciences Co. (NASDAQ:EXAS) Receives Consensus Rating of "Moderate Buy" from Brokerages

April 5, 2024 | investorplace.com

The 3 Best Cathie Wood Stocks to Buy in April 2024

April 4, 2024 | fool.com

1 Beaten-Down Cathie Wood Stock to Buy and Hold

April 4, 2024 | businesswire.com

Exact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to Inform Treatment

April 2, 2024 | benzinga.com

Exact Sciences's Options Frenzy: What You Need to Know

April 2, 2024 | seekingalpha.com

Exact Sciences: Cancer Battle Continues, Shares Likely To Plateau

April 2, 2024 | finance.yahoo.com

Exact Sciences, A Cathie Wood Stock, Surges As Rival Colon Cancer Test Pales

March 28, 2024 | msn.com

Exact Sciences gains after data for novel cancer screening test

March 28, 2024 | businesswire.com

Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer

March 27, 2024 | finance.yahoo.com

Exact Sciences Named 2024 Gallup Exceptional Workplace Award Winner

March 26, 2024 | investorplace.com

3 Growth Stocks to Buy at 52-Week Lows in March

See More Headlines

Receive EXAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/21/2024
Today: 4/17/2024
Next Earnings (Confirmed): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Medical laboratories
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:EXAS
CUSIP: 30063P10
CIK: 1124140
Web: www.exactsciences.com
Phone: (608) 284-5700
Fax: 608-284-5701
Employees: 6,600
Year Founded: 1995

Price Target and Rating

Average Stock Price Target: $97.44
High Stock Price Target: $121.00
Low Stock Price Target: $73.00
Potential Upside/Downside: +54.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.86
Research Coverage: 14 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.14)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-204,150,000.00
Net Margins: -8.17%
Pretax Margin: -8.07%
Return on Equity: -6.60%
Return on Assets: -3.20%

Debt

Debt-to-Equity Ratio: 0.74
Current Ratio: 2.32
Quick Ratio: 2.07

Sales & Book Value

Annual Sales: $2.50 billion
Price / Sales: 4.59
Cash Flow: $0.02 per share
Price / Cash Flow: 3,837.19
Book Value: $17.39 per share
Price / Book: 3.64

Miscellaneous

Outstanding Shares: 181,530,000
Free Float: 179,171,000
Market Cap: $11.48 billion
Optionable: Optionable
Beta: 1.25

Social Links

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Mr. Kevin T. Conroy (Age 58)
Chairman of The Board & CEO
Comp: $1.54M
Mr. Jeffrey T. Elliott CFA (Age 46)
EVP & CFO
Comp: $518.13k
Ms. Sarah Condella (Age 43)
Executive Vice President of Human Resources
Comp: $742.76k
Mr. Everett V. Cunningham (Age 58)
Chief Commercial Officer
Comp: $1.34M
Dr. Jorge A. Garces Ph.D. (Age 52)
Chief Science Officer
Mr. Nassar Nizami
Chief Information Officer
Ms. Megan Jones
Associate Manager of Investor Relations
Mr. Tim Caprez
Chief Compliance Counsel & VP
Mr. James Herriott (Age 44)
Senior VP, General Counsel & Secretary
Mr. Vic Parker
Head of Sales

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

EXAS Stock Analysis - Frequently Asked Questions

Should I buy or sell Exact Sciences stock right now?: 14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Exact Sciences in the last twelve months. There are currently 2 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" EXAS shares.
View EXAS analyst ratings or view top-rated stocks.
What is Exact Sciences' stock price target for 2024?: 14 Wall Street analysts have issued 1-year price objectives for Exact Sciences' shares. Their EXAS share price targets range from $73.00 to $121.00. On average, they anticipate the company's share price to reach $97.44 in the next year. This suggests a possible upside of 54.1% from the stock's current price.
View analysts price targets for EXAS or view top-rated stocks among Wall Street analysts.
How have EXAS shares performed in 2024?: Exact Sciences' stock was trading at $73.98 at the start of the year. Since then, EXAS shares have decreased by 14.5% and is now trading at $63.22.
View the best growth stocks for 2024 here.
When is Exact Sciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our EXAS earnings forecast.
How can I listen to Exact Sciences' earnings call?: Exact Sciences will be holding an earnings conference call on Wednesday, May 8th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.
How were Exact Sciences' earnings last quarter?: Exact Sciences Co. (NASDAQ:EXAS) posted its earnings results on Wednesday, February, 21st. The medical research company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.26. The medical research company earned $646.89 million during the quarter, compared to analysts' expectations of $638.83 million. Exact Sciences had a negative net margin of 8.17% and a negative trailing twelve-month return on equity of 6.60%. Exact Sciences's quarterly revenue was up 17.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.72) EPS.
What ETFs hold Exact Sciences' stock?: ETFs with the largest weight of Exact Sciences (NASDAQ:EXAS) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Principal Healthcare Innovators ETF (BTEC), Simplify Health Care ETF (PINK), First Trust NYSE Arca Biotechnology Index Fund (FBT), VanEck Biotech ETF (BBH), Alger Mid Cap 40 ETF (FRTY) and Goldman Sachs Future Health Care Equity ETF (GDOC).

What guidance has Exact Sciences issued on next quarter's earnings?: Exact Sciences issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.8 billion-$2.9 billion, compared to the consensus revenue estimate of $2.8 billion.
What is Kevin T. Conroy's approval rating as Exact Sciences' CEO?: 328 employees have rated Exact Sciences Chief Executive Officer Kevin T. Conroy on Glassdoor.com. Kevin T. Conroy has an approval rating of 97% among the company's employees. This puts Kevin T. Conroy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 69.0% of employees surveyed would recommend working at Exact Sciences to a friend.
What other stocks do shareholders of Exact Sciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Exact Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Salesforce (CRM), PayPal (PYPL), Block (SQ), Advanced Micro Devices (AMD), Walt Disney (DIS) and AbbVie (ABBV).
Who are Exact Sciences' major shareholders?: Exact Sciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Global Assets Advisory LLC (0.14%), Factory Mutual Insurance Co. (0.10%), Thompson Investment Management Inc. (0.09%), Traynor Capital Management Inc. (0.05%), Beech Hill Advisors Inc. (0.03%) and Gateway Investment Advisers LLC (0.02%). Insiders that own company stock include Brian Baranick, Canada Pension Plan Investment, D Scott Coward, Daniel J Levangie, Everett Cunningham, Jacob A Orville, James Edward Doyle, James Herriott, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy and Sarah Condella.
View institutional ownership trends.
How do I buy shares of Exact Sciences?: Shares of EXAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
Does Exact Sciences have any subsidiaries?: The following companies are subsidiares of Exact Sciences: Armune BioScience, Ashion Analytics, Base Genomics Limited, Biomatrica Inc., Exact Sciences Development Company LLC, Exact Sciences Laboratories LLC, Genomic Health Inc., Genomic Health International Holdings LLC, Paradigm Diagnostics Inc., Sampleminded Inc., Thrive Earlier Detection Corporation, and Viomics Inc..
Read More

This page (NASDAQ:EXAS) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial